Adding Value Beyond the 3rd Call
HCP feels they have the information regarding Assessments and BBBM. No need to see the TM ever again.
How to set expectation for follow up calls?
22%, 35%, 60%
What are percentages of slowing cognitive and function decline in various cohorts of Kisunla registration trial?
Unknown customer had 1 positive BBBM
How to vet a new customer?
Alzheimer’s treatment is generally covered on FFS Medicare without PA.
How is coverage for ATT therapy?
HCP doesnt have time to do screening, just refers concerned patients to neuro?
What cognitive assessment are you using? How long does it take the average patient to access a neuro appointment? Would your patients trust you more to do an initial assessment? Are you aware that Medicare covers a separate visit to more thoroughly assess your patient’s function and develop a care plan?
20 to 27
What were the baseline characteristic MMSE scores for patients in Kisunla’s registration trial?
HCP with service calls only, but no direct contact has 1 positive BBBM.
Can we create an office champ in absence of HCP interaction? Is there a P2P opportunity?
Covered for patients with diagnosis of MCI or Mild Dementia to detect the evidence of AD pathology and amyloid.
What is P-Tau 217 assay.
HCP told you they ordered BBBM but has yet to see patients back to discuss findings.
What were the results and when do you plan to see them? May I follow up with you to after that time to support you and your staff with the referral/treatment proces?
7%, 47%, 69%
What percentage of patients were able to stop treatment in the core trial at 6, 12, 18 months?
HCP has 3 positive BBBM and alert saying to send a VAE, but no email address.
Who in the office can provide information of preferred method of contact? If face to face possible or good email address? Will they deliver a handwritten note? Is P2P possible?
Lilly can partner with the treating HCP office to conduct benefit investigation to help each patient understand individual costs of treatment.
How do we answer an HCPs cost concern for Kisunla?
HCP has ordered and discussed BBBM results with patient, but yet to refer to specialist.
Is the hesitation on your part or the patients? How was that difficult conversation received by the patient?
82% of participants
What is the percentage of patients who stopped treatment at 12 months in the core registration trial and had negative amyloid PET at 3 years?
An office has 3 providers and 4 positive BBBM among them. The office is no see/no sample. You can drop off educational materials, but not talk with HCP or staff.
Can you invite out to P2P program?
$700
How much the AWC for a vial of Kisunla?
HCP claims they have not seen a patient with symptoms of MCI.
To clarify, you have not identified a MCI patient as of yet, because we know you have seen one? How often are you doing annual wellness visits for the an over 65 pt? What signs and symptoms will trigger you to do a formal cognitive assessment?
Reduction from 57% to 24%
What is the Trailblazer - Alz 6, ApoE4 homozygote reduction for Aria-E from original dishing to gradual titration dosing?
An office has 4 providers which you have had 3 lunches with in the past. Since, 15 positive BBBM among them. HCPs are only accessible during lunch or sample drops. Sent VAEs unopened. No lunch availability until 2026.
Is referral coordinator accessible? Plan a P2P program around the specific office? In generalized way, can BBBM data be used to get past gatekeeper?
I educate all my patients that there is Alz treatment, but that it is not affordable.
Is this your experience with an actual patient or your educated guess? What is the cost of not testing/referring? It is too expensive compared to what…long term care? Do your patients have loved ones that will be impacted by their eventual decline and dependency?